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Summary In a recent comparative genomic hybridization (CGH) study of a panel of sarcomas, we detected recurrent amplification of
1q21-q22 in soft tissue and bone tumours. Amplification of this region had not previously been associated with sarcoma development, but
occasional amplification of CACY/S100A6 and MUC1 in 1q21 had been reported for melanoma and breast carcinoma respectively. Initial
screening by Southern blot analysis showed amplification of S100A6, FLG and SPRR3 in several sarcomas and, in a first attempt to
characterize the 1q21-q22 amplicon in more detail, we have now investigated the amplification status of these and 11 other markers in the
region in 35 sarcoma samples. FLG was the most frequently amplified gene, and the markers located in the same 4.5-Mb region as FLG
showed a higher incidence of amplification than the more distal ones. However, for most of the 14 markers, amplification levels were low, and
only APOA2 and the anonymous marker D1S3620 showed high-level amplifications (> tenfold increases) in one sample each. We used
fluorescence in situ hybridization (FISH) to determine the amplification patterns of two overlapping yeast artificial chromosomes (YACs)
covering the region between Dl S3620 and FLG (789f2 and 764a1), as well as two more distally located YACs in nine selected samples. Six
samples had amplification of the YAC containing DlS3620 and, in three, 764a1 was also included. Five of these tumours showed normal
copies of the more distal YACs; thus, it seems likely that an important gene may be located within 789f2, or very close. Two samples had high
copy numbers of the most distal YACs. Taken together, FISH and molecular analyses indicate complex amplification patterns in 1q21-q22
with at least two amplicons: one located near Dl S3620/789f2 and one more distal.
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Cytogenetic studies have demonstrated recurrent aberrations of
chromosome 1, including deletions, translocations, trisomies and
amplifications, in solid tumours as well as in haematological
diseases (Dracopoli et al, 1994; Weith et al, 1996). Alterations of
the long arm ofchromosome 1 are found both in leukaemias and in
solid tumours, and are among the most common chromosomal
anomalies in human neoplasia. The aberrations can be seen as
trisomy of the entire long arm (Oshimura et al, 1976), as an
isochromosome lq (Kovacs, 1978) or as trisomy or duplication of
a smaller region, especially lq23-lq32 (Rowley, 1977). It has
been suggested that three or more copies of a gene (or genes) in
this region provide a selective advantage to cancer cells.
Furthermore, the finding of partial or complete lq trisomy being
more frequent in recurrent than in primary tumours could suggest
that this change may be associated with tumourprogression (Weith
et al, 1996).
Among solid tumours, Iq alterations had previously been
reported for breast, lung and germ cell tumours. In breast cancer,
comparative genomic hybridization (CGH), a method by which
whole genomes may be surveyed for DNA sequence copy number
changes (A Kallioniemi et al, 1992, O-P Kallioniemi et al, 1994),
has demonstrated frequent gains ofthe whole long arm ofchromo-
some 1 (A Kallioniemi et al, 1994; Muleris et al, 1994). However,
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there have been few reports on amplification of specific genes
located to chromosome 1. Amplification of the MYCLI gene at
lp32 seems to be a common aberration in small-cell lung cancer
(Nau et al, 1985; Makela et al, 1991) but has not been found in
other tumour types (Dracopoli et al, 1994; Weith et al, 1996).
Some melanoma cell lines show low-level amplification (or dupli-
cation) of CACY/SJOOA6', encoding calcyclin (Weterman et al,
1992). This gene is a member of the SIOOA family of calcium-
binding proteins located within a cluster of SIOOA genes in lq21
(Schafer et al, 1995; Schafer and Heizmann, 1996; Maelandsmo
et al, 1997). Another gene in lq21-q22, MUCI, coding for the
epithelial tumour-associated antigen mucin 1 (Tsarfati et al, 1990),
was found to be amplified in some breast cancers (Bieche et al,
1995; Bieche and Lidereau, 1997).
We recently studied DNA amplification in soft-tissue and bone
sarcomas by CGH (Forus et al, 1995a,b) and found amplifications
in about 50% of the tumours analysed. The amplicons most
frequently observed were the well-characterized one at 12qI3-q15
and a novel one at lq21-q22. At the same time, gain of lq was
reported in some osteosarcomas, but was not considered a
common abnormality ofsuch tumours (Tarkkanen et al, 1995). We
found that amplicons at lq2l1-q22 were more frequent than those
at 12ql3-q15, which have been detected in a substantial number
of the sarcomas analysed (Forus et al, 1993, 1994; Khatib et al,
1993; Maelandsmo et al, 1995; Nilbert et al, 1995; Berner et al,
1996). These observations could indicate that increased copy
'A new logical nomenclature for this gene family has recently been approved by
Genome Data Base (Schafer et al., 1995) and will be used throughout this paper.
Accordingly, CACYhas been renamed SJOOA6.
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numbers ofone or more ofthe genes in the 1q21-q22 region could
play a role in the development or progression of at least some
sarcoma subtypes. Gains of lq material have also been reported by
other investigators as an occasional event in rhabdomyosarcomas
(Weber-Hall et al, 1996) and more frequently in liposarcomas
(Szymanska et al, 1996, 1997) and Ewing's sarcomas (Armengol
et al, 1997), often involving lq21-q22 as a minimal common
region of gain. Recently, Larramendy et al (1997) reported infre-
quent gain of 1q material in malignant fibrous histiocytomas
(MFHs), but with a more distal minimal common region, 1q24.
It might be significant that many ofthe tumours with amplifica-
tions of 1q are well-differentiated liposarcomas (WDLPS) and
MFHs tumours that are often characterized by giant marker chro-
mosomes containing amplified segments from various chromo-
somes (Heim et al, 1987; Orndal et al, 1992; Dal Cin et al, 1993;
Pedeutour et al, 1993; Nilbert et al, 1994). In most WDLPS, such
marker chromosomes carry segments from chromosome 12, corre-
lating with MDM2 amplification (Pedeutour et al, 1994), but we
have recently found that some have markers that also carry
chromosome 1 material, and in most of these amplification of
Iq21-q22 could be demonstrated by CGH (Pedeutour et al, 1998).
In an attempt to characterize the 1q21-q22 amplicon in
sarcomas, we have analysed the amplification pattern of SIOOA6
and ten other markers within the same 4.5 Mb region of lq2I-q22,
in addition to MUCI and two genes from other parts ofthe region,
in 35 sarcomas previously studied by CGH. We have also used
fluorescence in situ hybridization (FISH) to determine chromo-
some 1 and 2 copy numbers, as well as amplification patterns of
four YAC clones from the 1q21-q22 region.
MATERIALS AND METHODS
Specimens
Thirty-five human sarcomas ofvarious subtypes were analysed. In
a previous study, 16 ofthese had been found to have amplification
of lq2l-q22 by CGH, whereas the other 19 had not (Table
1)(Forus et al, 1995a,b). The samples were obtained directly from
21 patients with sarcomas of various subtypes, from 13 different
sarcoma samples grown subcutaneously as xenografts in nude
mice and from the liposarcoma cell line SW872 (ATCC). All
tumours were classified according to the WHO International
Histological Classification ofTumours (Schajowich, 1993; Weiss,
1994). The tissues were cut in small pieces and frozen in liquid
nitrogen immediately after surgery and were stored at -70°C.
Blood samples from healthy individuals were used as controls.
Southern blot analysis
DNA extraction from tumour samples, preparation of filter blots
and hybridization was performed as described previously (Forus et
al, 1993). First, amplification patterns often different markers and
genes were analysed: FLG, IVL, SPRR3, SPRR]B, SPRR2A,
SOOA6 (CACY) and SIOOA2 (SIOOL), all of which are physically
mapped within 2 Mb and are part of a 6-Mb YAC contig in 1q21
(Marenholz et al, 1996), as well as two markers that have
been mapped distal to the 6-Mb contig in the order CRP-APOA2
and MUCI (Weterman et al, 1996; Chromosome 1 www page
http://linkage.rockefeller.edu/chrI/).
Based on the results obtained with these probes, we later
included some additional anonymous clones that map proximal to
FLG (DIS3620 and D1S3623) and distal to S10OA2 (D1S3625
and D1S3628) (Marenholz et al, 1996).
Southern blots were sequentially hybridized to probes from
each locus and to a control probe from chromosome 2 (APOB)
(Huang et al, 1985). Quantitation of signal intensity was achieved
by two-dimensional densitometry on a Molecular Dynamics laser
densitometer. The net signals from specific bands were corrected
for unequal sample loading by calibration relative to the signal
obtained with the APOB control probe. Mean signals from three
(or more) different blots were used to measure the amplification
levels in the tumour. As the percentage of tumour cells versus
normal cells for each sample was not known, the actual amplifica-
tion levels in the tumour cells may be higher than the presented
values.
The signals were compared with signals from control samples
with a normal karyotype (leukocytes) and interpreted as described.
Borderline amplification - a signal two- to threefold more intense
than signals from normal samples (i.e. average probe/APOB ratio
for tumour divided by average probe/APOB ratio for normal
sample between 2.0 and 2.9); low level - three- to fivefold increase
(tumour-normal value between 3.0 and 4.9); moderate - five- to
tenfold increase (tumor-normal value between 5.0 and 9.9); and
high - > tenfold increase (tumour-normal value 10 or higher).
Fluorescent in situ hybridization (FISH) to interphase
nuclei
Preparation ofinterphase nuclei
Frozen tumour tissue was pulverized in liquid nitrogen, transferred
to a centrifuge tube and immediately fixed in 3:1 methanol-acetic
acid. Aftercentrifugation, the pellet was resuspended in 60% acetic
acid. Two or three drops ofthe suspension were applied onto slides
(Menzel Superfrost) prewarmed to 45-50°C, and left to dry at the
same temperature. Slides were stored at-20°C before use.
Preparation ofprobes
YAC DNA was labelled with biotin-14-dATP or digoxygenin-11-
dUTP (Boehringer Mannheim, Germany) by nick translation
(GibcoBRL Life Technologies, USA). For each hybridization,
200-300 ng oflabelled YAC DNA was prehybridized with a 50- to
100-fold excess of human Cot-I DNA and 2-5 ,tg of yeast DNA,
whereas biotin- or digoxygenin-labelled centromere probes were
simply premixed with human placenta DNA (Sigma, St. Louis,
MO, USA). Subsequently, the probes were dissolved in 50%
formamide/10% dextran sulphate/0.3 M sodium chloride, 30 mM
sodium citrate (2 x SSC).
In situ hybridization
Slides were thawed and immersed in 75% ethanol at 4°C for 1-2 h
before use, air dried and denatured in 70% formamide/2 x SSC,
pH 8.0 for 3 min at 74°C, washed three times in ice cold 2 x SSC,
dehydrated in ethanol (70%, 90%, 96% and 100%) and air dried.
Thereafter, slides were treated with proteinase K (0.1 ,ug ml-' in
20 mm Tris-HCl/2 mm calcium chloride, pH 7.0) for 10 min at
room temperature, washed in 2 x SSC, dehydrated and air dried.
Probes were denatured for 10 min at 80°C, prehybridized for
15-30 min at 37°C and applied to slides at room temperature.
Hybridization was done overnight at 37°C. After hybridization,
the slides were washed three times for 10 min in 50% formamide/
2 x SSC at 45°C and then three times for 10 min in 2 x SSC at
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Table 1 Histopathological characteristics and 1q21-q22 amplification data of the 35 sarcomas analysed
Tumour Histological subtype Sample Histological Location Preoperative Amplification
from grade treatment
by CGH Mol probes
LMS2x Rec 3 Arm No 1q21-q23 Yes
LMS14 Prim 4 Lung No 1q21-q23 Yes
LMS15 Prim 3 Abdomen No 1q21-q23 Yes
LS2 Well-differentiated Prim 1 Thigh No 1q21-q22 Yes
LS3x Pleomorphic Prim 4 Abdomen No 1q21-q22 Yes
LS5x Round cell Prim 4 Abdomen No No
LS6 Well-differentiated Prim 1 Gluteal No 1q21-q22 Yes
LS7 Sclerosing/well-differentiated Prim 2 Paraspinal No No
LS9 Well-differentiated/lipoma like Prim 1 Thigh No 1q21-q22 Yes
LS10 Undifferentiated Cell line No
LS13 Well-differentiated Prim 1 Thigh No 1q21-q22 Yes
LS15 Myxoid/round cell Prim 4 Gluteal No No
LS18 Round cell Prim 4 Abdomen No No
LS21 Well-differentiated Prim 2 Abdomen No 1q21-q22 Yes
LS22 Various differentiation Rec 3 Abdomen Chemotherapy No Yes
LS26 Myxoid/round cell Prim 3 Groin No No
LS28 Pleomorphic/round cell Prim 4 Abdomen No No
LS32 Mixed Prim 3 Thigh No No
MFH3x Prim 4 Retroperitoneal No No Yes
MFH19 Rec 4 Thigh No 1q21-q22/23 Yes
MFH21 Prim 4 Thorax No 1q21-q22 Yes
MFH25 Prim 4 Thigh No No
MFH36 Prim 4 Shoulder No 1pter-q22 Yes
MS2x Prim 3/4 Leg No No
MS8x Prim 3 Gluteal No 1q21-q22 Yes
OS4x Prim 4 Femur Chemotherapy 1q11-q23 Yes
OS6x Prim 4 Femur Chemotherapy No
OS7x Prim 4 Femur Chemotherapy No
OS8x Met 4 Femur Chemotherapy No
OS9x Prim 3/4 Femur No 1q21-q25 Yes
OSl1x Prim 4 Femur No No
OS13x Met 4 Lung Chemotherapya 1q21-q23 Yes
OS21 Prim 4 Thigh Chemotherapy No Yes
OS29 Prim 4 Pelvis Chemotherapyb No
PNET1 Prim 4 Leg No No
LMS, leiomyosarcoma; LS, liposarcoma; MFH, malignant fibrous histiocytoma; MS, malignant peripheral nerve sheath tumour (malignant schwannoma); OS,
osteosarcoma; PNET = primitive neuroectodermal tumour. For the liposarcomas, the histological subtype is indicated if known. The stage, histological grade
and localization of the tumour sample analysed are indicated. Prim, primary tumour; Rec, recurrent; Met, metastasis. For each sample it is indicated whether
amplification of 1q21-q22 could be demonstrated by CGH and/or molecular analysis (Mol probes, > twofold increase in gene dosage). LS10 is a cell line. Some
of the patients received chemo- or radiotherapy before surgery. aThis patient received adjuvant chemotherapy after the primary tumour, which was excised 4
years before the removal of the sample analysed here. bThis was a therapy-induced osteosarcoma; the patient had Ewing's sarcoma 5 years before this tumour
and received chemo- and radiotherapy.
60°C. For detection, we used fluorescein isothiocyanate (FITC)-
conjugated anti-digoxygenin (Boehringer Mannheim), avidin-
conjugated Texas Red (Vector Laboratories, Burlingame, CA,
USA) or avidin-conjugated CY3 (Amersham Life Science, Little
Chalfont, UK). The interphase nuclei were counterstained with
4',6-diamino-2-phenylindole (DAPI) and mounted in anti-fade
solution (Vector Laboratories).
Evaluation ofresults
Hybridized slides were examined visually using a Zeiss Axioplan
microscope equipped with appropriate single-bypass filters for
exitation of DAPI, FITC, Texas Red and rhodamine/CY3, and
double bypass filters for excitation of DAPI/rhodamine and
DAPI/FITC. The slides were manually scanned at 63x or lOOx
magnification with DAPI excitation to localize the interphases.
Nuclei that were eitherpartially ortotally overlapping or not intact
were not analysed. For each probe, the number of spots was
counted in at least 150 nuclei.
'Probes
cDNA andgenomicprobes
The following probes were used: pHX5 FLG (Presland et al,
1992), containing a part ofthe coding region from the 3' end ofthe
human filaggrin gene, kindly provided by Drs Fleckman and
Presland; IVL (pI-2) (Eckert and Green, 1986) containing the 3'
end cDNA of human involucrin, kindly provided by Drs Easley
and Green; cDNA probes for the genes SPRRIB, SPRR2A and
SPRR3 (Gibbs et al, 1993; Hohl et al, 1995), kindly provided by
Dr Backendorf; a cDNA clone for human calcyclin (CACYI
SJOOA6)(pMW1)(Weterman et al, 1992), kindly provided by Dr
Bloemers, and CAN19; a near full-length cDNA probe for the
human SJOOLISJOOA2 (Lee et al, 1992), kindly provided by Dr
Sager. All these probes are located within the same 2-Mb region in
1q21 (Mahrenholz et al, 1996). Three other genes from Iq21-q22
were also checked: pCRP-5, a cDNA clone for human C-reactive
protein (CRP) (Tucci et al, 1983); cDNA for apolipoprotein All
(APOA2) (Rogne et al, 1989); and pMUClO, a genomic clone for
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Figure 1 Representative Southern blot hybridizations demonstrating the amplification pattern of the FLG, SPRR1B, SPRR2A, SPRR3and S100A21oci (A),
DlS3620 and Dl S3623 (B) and APOA2 (C). DNA from each sample was digested with Hindlll and sequentially hybridized to probes as indicated to the right.
Leucocyte DNA was included as a control for normal copy number, and a probe for APOB was used to calibrate for unequal sample loading. An 'A' below a
panel indicates that the corresponding gene is amplified more than threefold, an (A) indicates borderline amplification (signal two to three times more intense
than the signal from normal DNA). LS, liposarcoma; OS, osteosarcoma; MFH, malignant fibrous histiocytoma; MS, malignant peripheral nerve sheath tumour
(malignant schwannoma)
the epithelial tumour-associated antigen MUC1 (Swallow et al,
1987) (UK DNA probe bank). Anonymous probes from the 1q21
region that are located approximately 4 Mb apart were: D1S3620
and D1S3623, which are centromeric to FLG, and D1S3625 and
D1S3628, which are telomeric to CACYIS]O0A6 (Marenholz et al,
1996). A cDNA probe for the APOB gene on human chromosome
2, kindly provided by Dr Breslow (Huang et al, 1985), was used to
calibrate for unequal sample loading.
Centromere probes
The centromere probes used were biotin or digoxygenin-labelled
human chromosome 1 cc-satellite (DIZ5) and human chromosome
2 ac-satellite (D2Z) (Oncor, Gaithersburg, MD, USA).
Yeast artificial chromosome (YAC) clones
We used two YACs from the Centre D'Etude du Polymorphisme
Humain (CEPH) mega-YAC library, 789f2 and 764al (Marenholz
et al, 1996). These YACs are part of a 6-Mb contig in 1q21 and
cover the region from FLG to DIS3620 (Marenholz et al, 1996).
The two other YACs, 935b12 and 883h6, were from the CEPH
library described by Albertsen et al (1990) and have been mapped
to the 1q21-q22/q23 region (CEPH-Genethon map).
RESULTS
Southern blot analysis
Initial screening of selected tumour samples using probes for
SJOOA6, FLG and SPRR3, which are located in the same 2-Mb
region of 1q21-q22, detected amplifications at various levels in all
the tumours tested and, therefore, these and four other markers in
the region were analysed in more samples. We also included
MUCI, as this gene has been reported to be amplified in breast
cancer, and two other genes in the region, CRP and APOA2, for
which probes were available.
All the probes from 1q21-q22 detected amplification in some of
the samples (Figures 1 and 2). Nine samples had more than a
threefold increase in gene dosage of one or more of the genes
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Figure 2 Amplification of 1q21-q22 in human sarcomas. The upper part of the figure shows a composite map of 1q21-q22 adapted from physical (Marenholz
et al, 1996; Schafer and Heizmann, 1996) and genetic (Dracopoli et al, 1994; Weterman et al, 1996) mapping data. Loci are listed in their order from the
centromeric (left) to the telomeric (right) side. An empty column indicates > 200 kb distance between two loci. Between S100A2 and S100A6 there are at least
three additional Si OOA genes that have not been tested in this study (Schafer et al, 1995; Schafer and Heizmann, 1996). The physical distances between
S100A6, CRPand APOA2 are not known, but the genetic distance between S100A6 and CRP is around 9 cM (Murray et al, 1994), as discussed by Mahrenholz
et al (1996). MUC1 has not been located relative to the other genes, but linkage analysis gives the order (centromere to telomere) MUC1-CRP-APOA2
(Dracopoli et al, 1994; Weith et al, 1996). The densitometrically determined levels of amplification are divided into four categories as indicated, based on
average signals from at least three different blots. Tumour types and numbers are given to the left [LMS, leiomyosarcoma; LS, liposarcoma; MFH, malignant
fibrous histiocytoma; MS, malignant peripheral nerve sheath tumour (malignant schwannoma); OS, osteosarcoma]. The number of samples with amplification
(two to three fold increase or more) of each locus is listed below. The CGH column lists the previously detected 1q21-q22 amplifications (Forus et al, 1995a,b).
A '-' sign = no 1q21-q22 amplification detected by CGH. ND, not done
(Figure 2) and ten other samples showed borderline amplification
(two- to threefold increase). Among these were three samples in
which no gain of lq21-q22 was detected by CGH (LS22, MFH3x
and OS21). The remaining 16 tumours had a normal copy number
of all the genes tested.
FLG, encoding human epidermal profilaggrin (Presland et al,
1992), was the most frequently amplified gene, but in most
samples only borderline amplification of this gene was found. The
genes localized close to FLG (IVL, SPRR3, SPRRIB, SPRR2A,
SIOOA6 and SIOOA2), were amplified in fewer samples and were
also at borderline or low levels in most cases. However, SPRR3,
SPRR2A, SIOOA6 and SIOOA2 showed amplification levels above
fivefold in some samples (LMS2x, LS 13 and MS8x). Three
samples had amplification of all seven genes at variable levels
(Figure 2, LMS2x, LS2 and LS13). Among the loci that has not
been mapped to the above-mentioned 6-Mb contig, CRP was the
only one that was included in the amplicon in LS6, and APOA2
was the only gene amplified above tenfold in one of the lipo-
sarcomas (LS21). MUCI was amplified in five samples, i.e. in
fewer cases than any of the other genes tested.
The region between FLG and SIOOA2 was more frequently
amplified than loci located telomeric to this interval (MUCI,
APOA2 and CRP). We therefore determined the amplification
pattems also of some additional anonymous clones that map
proximal to FLG (D1S3620 and D1S3623) and distal to SJOOA2
(DIS3625 and D1S3628), delineating a 4.5-Mb region in
1q21-q22 (Marenholz et al, 1996). Copy numbers of these probes
were determined in those 19 samples that had previously revealed
amplification of one or more of the genes. As shown in Figure 2,
D1S3623, located proximal but close to FLG (Marenholz et al,
1996), was as frequently amplified as FLG, whereas the more
proximal marker, D1S3620, was amplified in fewer cases.
D1S3620 was highly amplified in MS8x, whereas D1S3623 and
FLG showed normal copy numbers, but the sample had another
amplified cluster covering IVL through SPRR2A. D1S3625 and
D1S3628, localized distal to S1]OA2, showed a similar amplifica-
tion pattern to S1OOA2.
FISH analysis of chromosome 1 and 2 copy numbers
Although the variable gene dosages observed along the chromo-
some were consistent with regional low-level amplification, we
wanted to ascertain that the tumours did not have extra copies of
chromosome 1 or abnormal ratios between chromosome 1 and
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Table 2 Selected tumour samples analysed by FISH using centromere probes and YACs in 1q21-q22
Tumour Centromere analysis YAC analysis
No. 1 No. 2 (No. 1: No. 2) 789f2 764a1 935b12 883h6
LS2 2.3 2.1 1.1 43% 43% 7% 5%
LS3x 2.0 2.0 1.0 33% (3-4s) 43% (3-4s) 83% 73%
LS6 2.1 2.0 1.1 47% 11% (3-4s) 3% 5%
LS13 2.2 2.2 1.0 51% 55% 4% 5%
4.5% (4-6s)
LS21a 2.2 2.1 1.0 46% 16% (3-4s) 38% (3-4s) 46%
18% (4-6s) 18% (4-6s)
LS21b 2.2 2.1 1.0 0% 2% (4s) 0% 0%
LS22 4.2 4.0 1.1 NA NA NA NA
MFH3x 5.7 5.8 1.0 NA NA NA NA
MFH25 2.2 2.1 1.1 5.7% 5% 1% 1%
MFH36 2.4 2.1 1.1 75% 75% 19.5% (3-4s) 16% (3-4s)
MS2x 2.2 2.2 1.0 5% 2% 1.5% 0.5%
MS8x 2.0 2.0 1.0 85% 6% 18% (3-4s) 3%
OS4x 4.5 5.1 0.9 NA NA NA NA
Centromere 1 and 2 as well as four YAC clones from 1q21-q22/q23 have been analysed by FISH in selected tumours with amplifications in 1q21-q22 detected
by CGH and/or molecular analysis and in two samples with normal copy numbers of the genes (MS2x and MFH25). For each sample, at least 150-200 nuclei
were counted. YACs 789f2 and 764a1 are partly overlapping. YACs 935b12 and 883h6 are located very close together, but more distal (not shown).
Centromere analyses: for each sample, the average centromere counts are shown. All tumours had a balanced chromosome 1 :2 ratio, but LS22, MFH3x and
OS4x had abnormal (increased) chromosome numbers and were not analysed with the YACs (NA). YAC analyses: for each sample, the percentage of nuclei
with abnormal copy numbers is shown. Bold text: high copy number gains of a YAC (at least ten signals). Underlined text: three to four YAC signals in more than
30% of the nuclei. In two samples with amplification of 789f2 (LS13) and 789f2 and 883h6 (LS21), a fraction of the nuclei showed four to six signals, as
indicated by split boxes. Italic: 10-20% of the nuclei showed three to four signals. In addition, some samples gave three to four signals with one or two of the
YACs tested in less than 10% of the nuclei. Notably, in LS21, two different parts of the tumour (a, b) showed different amplification patterns.
chromosome 2 (used for normalization). We therefore determined
the copy numbers of centromeres 1 and 2 by interphase FISH on
nuclei from ten of the samples with amplicons detected by molec-
ular analysis and/or CGH, as well as two tumours with apparently
normal copy numbers of all the markers tested (MS2x and
MFH252). All the samples tested had similar mean numbers of
centromere 1 and 2 per nucleus (Table 2). Seven of the tumours
showed normal centromere counts in most of the nuclei, whereas
three (LS22, MFH3x and OS4x) had four to six copies of each.
FISH analysis of YAC copy numbers
The molecular results gave no clear indications as to whether the
region studied was likely to contain the core of the amplicon,
although the high amplification levels ofD4S3620 found in MS8x
could indicate that this marker was close. The region between
DlS3620 and FLG has not been mapped in detail, but two YACs
that cover this region, 789f2 and 764al, were available [the posi-
tions of these YACs was mapped by Mahrenholz et al (1996) and
are indicated in Figure 2]. We studied the amplification pattern of
these YACs only in samples with normal average cen 1 and cen 2
copy numbers, including seven tumours with amplifications in this
region and two control samples (MS2x and MFH25). The samples
with increased centromere 1 and 2 copies were excluded from the
study because it would be very difficult to obtain reliable results.
Two additional YACs were selected from the CEPH-Genethon
map of region lq21-q23 and mapped by FISH analysis distal to
764al (not shown). However, FISH on normal metaphases could
not determine whether 935b12 or 883h6 is the most distal YAC as
they gave overlapping signals. Results from FISH analyses with
these four YACs are shown in Table 2 and Figure 3.
As shown in Table 2, 789f2, covering D1S3620, detected high
copy numbers (more than ten, but in most samples uncountable) in
nuclei from five of the samples and three to four signals in one
(LS3x). However, there was considerable heterogeneity among the
nuclei. In MFH36 and MS8x, a major fraction of the nuclei (75%
or more) exhibited amplification; in the other samples, LS2, LS3x,
LS6 and LS13, only about 50% or less. 764a1, covering DIS3623,
detected high copy numbers in three samples and three or four
signals in one, but, except for MFH36, only about 50% of the
nuclei or less had these aberrations. The more distal YACs were
amplified in fewer samples. 883h6 and 935b12 detected high copy
numbers only in LS3x, involving more than 70% of the nuclei.
We analysed two different pieces from the last sample, LS21.
As shown in Table 2, considerable heterogeneity was detected: one
part ofthe tumour had no amplifications, whereas in the other part
789f2 and 883h6 showed high copy numbers. In addition, a frac-
tion of the nuclei also showed four to six signals with these two
YACs. 789f2 and 883h6 were always co-amplified in this part of
the tumour, but only in 46% of the nuclei analysed. The other
YACs, 764al and 935bl2, detected three or four signals in 16%
and 38% ofthe nuclei respectively.
For some samples, one or two of the YACs tested gave three or
four signals in a smaller fraction ofthe cells (less than 20%). As all
these samples showed higher amplification levels with at least one
of the other YACs, these aberrations were considered to be of less
importance.
DISCUSSION
Gain of chromosomal sequences, or amplification, is frequently
found in human cancers. Functional analysis and clinical
observations have supported the hypothesis that amplification and
'MFH25 was called MFH43 in a previous study (Forus et al, 1995a).
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Figure 3 FISH analysis using YACs from 1q21-q22/q23 on interphase nuclei from MFH36, MS8x and LS2. (A-C) interphase nuclei from MFH hybridized with
(A) digoxygenin (dig)-labelled 789f2 detected by FITC (in green) and biotin-labelled 764a1 detected by avidin-CY3 (in red), (B) biotin-labelled 883h6 and
(C) 935b12, detected by avidin-Cy3 (in red). YAC 789f2 and 764a1 detect amplification and were always co-amplified, but 789f2 is amplified at higher levels (A).
883h6 and 935b12 show normal copy numbers in most of the nuclei (883h6 gives three signals in one). (D and E) interphase nuclei from MS8x hybridized with
biotin-labelled 789f2 (D) and 935b12 (E). 789f2 detects high-level amplification whereas 935b12 gives normal signals. (F) interphase nucleus from LS2
hybridized with digoxygenin (dig)-labelled 789f2 (in green) and biotin-labelled 764a1 (in red). The YACs were always co-amplified, but also, here, 789f2 is
amplified at higher levels
overexpression of cellular oncogenes are important for tumori-
genesis or tumour progression (Alitalo and Schwab, 1986). In its
simplest form, one might expect that amplification and over-
expression of a single dominant (proto)oncogene could provide a
selective growth advantage to the tumour cells. Ifso, all amplicons
would contain this 'driver' gene and its closely flanking markers
and other amplified sequences would only be random passengers
ofthe amplicon. However, studies of 11q13 amplification in breast
cancer and 12q13-15 amplification in sarcomas have revealed
more complex situations with multiple amplification units and
several candidate genes in the same region (Gaudray et al, 1992;
Berneret al, 1996; Wolfet al, 1997).
We have previously demonstrated frequent amplification of the
12q13-15 segment, including the CDK4, MDM2 and HMGIC
genes, in human sarcomas (Forus et al, 1993; Maelandsmo et al,
1995; Berner et al, 1996, 1997). In addition, CGH analysis
detected amplification of the 1q2l-q22 region in even more
samples from this tumour panel (Forus et al, 1995a, b), indicating
that lq21-q22-located genes may also play an important role in
the development and/or progression of such tumours. Similar
observations have also been reported by other investigators
(Szymanska et al, 1996; Armengol et al, 1997).
In this first molecular analysis of the lq21-q22 amplifications
in sarcomas, we determined the amplification status of 11 markers
located in a region covering 4.5 Mb, including S10OA6, which had
been reported to be amplified in melanomas (Weterman et al,
1992). We also analysed three more distal markers, including
MUCI, amplified in some breast carcinomas (Bieche and
Lidereau, 1997; Bieche et al, 1995).
One would expect that markers closest to the 'core' of the
amplicon would be amplified most frequently and at the highest
levels. The most frequently amplified markers were moderately
increased in most of the samples, and only APOA2 and the anony-
mous marker DlS3620 were amplified more than tenfold in one
sample each (in LS21 and MS8x respectively). Thus, these criteria
were not fulfilled for any ofthe markers tested here. The relevance
ofthe moderate copy number increases is unclear at present, but it
seems likely that they are due to amplification processes within the
segment, probably selected for by one or more unknown onco-
gene(s) in the region.
As DIS3620 detected high-level amplification in one sample, we
analysed the region around this marker in more detail by FISH in
nine selected samples, using two partly overlapping YACs covering
sequences between DlS3620 and FLG. YAC 789f2, which includes
DlS3620 and extends towards D1S3623 (Figure 2), detected high
copy numbers in six ofthese nine tumours (LS2, LS6, LS13, LS21,
MFH36 and MS8x, Table 2), but in only one part ofLS21. The more
distal 764al was amplified in only three of these tumours (LS2,
LS13, and MFH36). No YACs near APOA2, the other region with
high-level amplification, were available, but we analysed the ampli-
fication pattern of935b12 and 883h6, which we have mapped distal
to 764al (Table 2). Like APOA2, both YACs detected amplification
in LS3x. In LS21, showing the highest copy numbers of APOA2,
only one part of the tumour showed amplification of 883h6, again
indicating tumour heterogeneity.
In five of the samples with amplification of 789f2, the more
distal YACs (935b12 and 883h6) showed normal copy numbers in
most of the nuclei. These results could suggest that in a subset of
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tumours a target gene is located within 789f2, or even more prox-
imal, whereas more distal sequences seem to be of less impor-
tance. In LS3x, on the other hand, the focus ofthe amplicon seems
to be more distal, i.e. in the region of 883h6, 935b12 and APOA2,
whereas LS21 may have at least two amplicons, one near 789f2
and another one in the region ofAPOA2 and 883h6. The presence
of multiple amplified regions on the lq arm in sarcomas has been
shown previously (Forus et al, 1995a).
It is somewhat puzzling that for most samples the high-level
amplifications detected by FISH were often found only in about
50% of the nuclei. One possibility is that the cells with normal
copy numbers in tumours with amplification are normal cells, in
which case the amplification levels determined from the Southern
analyses would be underestimated. However, such a large fraction
of normal cells would be surprising, e.g. in the homogeneous
WDLPS samples. Conversely, the variation in copy numbers
between the nuclei could be an indication of clonal variations
within the tumours and, then, Southern analysis would only reveal
the average copy numbers. This interpretation is supported by the
heterogeneous amplification status detected in some of the
tumours (e.g. LS21). It seems likely that the results shown here
(Table 2) reflect tumour heterogeneity as well as, to some extent,
the presence of normal cells. Tumour cell percentage in the
different pieces was not evaluated before DNA isolation, therefore
we do not know to what extent the presence of normal cells may
have affected the measured amplification levels.
Most of the samples analysed were from primary tumours of
histological grade 3 or 4 (Table 1), and there is no correlation
between malignancy grade or any other known clinical parameters
and the presence of Iq21-q22 amplifications. Many ofthe patients
with osteosarcoma have received chemotherapy before surgery, but
the presence ofthe 1q21-q22 amplicon and preoperative treatment
is not correlated. Therefore, it seems unlikely that such amplifica-
tions could be therapy induced. As the lq21-q22 amplicon is
present in primary as well as in recurrent and metastatic samples, it
is possible that amplification of oncogenes in this region plays a
role in the development ofthese tumours but may be less important
for progression and metastasis.
The previous CGH analyses of this tumour panel (Forus et al,
1995a,b), as well as other studies of osteosarcomas and liposar-
comas (Tarkkanen et al, 1995; Szymanska et al, 1996), indicate
that lq21-q22 amplifications are more frequent than those at
12qI3-q15 and thus may be ofgreat importance. In this first mole-
cular characterization ofthe Iq21-q22 amplifications in sarcomas,
we observed frequent but relatively low copy number increases for
most of the markers tested, but also some high-level amplifica-
tions. Taken together, our results indicate more than one core of
the amplicon and further analyses are required to determine impor-
tant sequences more precisely and to find the relevant genes.
ACKNOWLEDGEMENTS
This work was supported by the Norwegian Cancer Society and by
the European Commission through the Biomedicine and Health
project 'Integrated analysis of expression and chromosomal orga-
nization of genes localized on human chromosome lq21: implica-
tions for human disease and cancer' under BIOMED 2
(BMH4-CT96-0319). We are grateful to Drs Helgerud and H0ie
for providing the clinical samples, Dr Stenwig for histological
classification of the tumours, Ingo Marenholz (Berlin) and Dr
Bjerkehagen (Oslo) for valuable advice and support and Kjetil
Boye Pedersen for excellent technical assistance.
REFERENCES
Albertsen HM, Abderrahim H, Cann HM, Dausset J, Le Paslier D and Cohen D
(1990) Construction and characterisation of a yeast artificial chromosome
library containing seven haploid human genome equivalents. Proc NatlAcad
Sci USA 87: 4256-4260
Alitalo K and Schwab M (1986) Oncogene amplification in tumor cells. Ads' Cancer
Res 47: 235-281
Armengol G, Tarkkanen M. Virolainen M, Forus A, Valle J, Bohling T, Asko-
Seljavaara S, Blomquist C, Elomaa I, Karaharju E, Kivioja AH, Siimes MA,
Tukiainen E, Caballin MR, Myklebost 0 and Knuutila S (1997) Recurrent
gains of Iq8 and 12 in the Ewing family of tumours by comparative genomic
hybridisation. Br J Cancer 75: 1403-1409
Berner J-M, Forus A, El Kahloun A, Meltzer PS, Fodstad 0 and Myklebost 0
(1996) Separate amplified regions encompassing CDK4 and MDM2 in human
sarcomas. Genies Chroain Cancer 17: 254-259
Berner J-M, Meza-Zepeda LA, Kools PFJ, Forus A, Schoenmakers EFPM, Van de
Ven WJM, Fodstad 0 and Myklebost 0 (1997) HMGIC, the gene for an
architectural transcription factor, is amplified and rearranged in a subset of
human sarcomas. Oncogene 14: 2935-2941
Bieche I and Lidereau R (1997). A gene dosage effect is responsible for high
overexpression of the MUCI gene observed in human breast tumours. Cancer
Genet Cvtogenet 98: 75-80
Bieche I, Champeme M-H and Lidereau R (1995) Loss and gain ofdistinct regions
ofchromosome q in primary breast cancer. Clin Cancer Res 1: 123-127
Dal Cin P, Kools P, Sciot R, De Wever I. Van Damme B, Van de Ven W and Van den
Berghe H (1993) Cytogenetic and fluorescence in situ hybridization
investigation of ring chromosomes characterizing a specific pathologic
subgroup ofadipose tissue tumors. Canzcer Geniet Cytogenet 68: 85-90
Dracopoli NC, Bruns GAP, Brodeur GM, Landes GM, Matise TC, Seldin MF, Vance
JM and Weith A (1994) Report of the first international workshop on human
chromosome I mapping 1994. Cvtogenet Cell Genet 67: 144-165
Eckert RL and Green H (1986) Structure and evolution of the human involucrin
gene. Cell 46: 583-589
Forus A, Fl0renes VA, Maelandsmo GM, Meltzer PS, Fodstad 0 and Myklebost 0
(1993) Mapping of amplification units in the q 13-14 region of chromosome 12
in human sarcomas: some amplica do not include MDM2. Cell Growth Differ
4:1065-1070
Forus A, Fl0renes VA. Maelandsmo GM, Fodstad 0 and Myklebost 0 (1994)
12q13-14 amplica in human sarcomas without MDM2 include CDK4, SAS
and GADD153/CHOP. Cancer Getnet Cytogenet 77: 200
Forus A, Olde Weghuis D, Smeets D, Fodstad 0, Myklebost 0 and Geurts van
Kessel A (1995a) Comparative genomic hybridization analysis ofhumnan
sarcomas. I. Occurrence ofgenomic imbalances and identification of a novel
major amplicon at Iq21-q22 in soft tissue sarcomas. Getnes Chroini Canccer 14:
8-14
Forus A, Olde Weghuis D, Smeets D, Fodstad 0, Myklebost 0 and Geurts van
Kessel A (1995b) Comparative genomic hybridization analysis of human
sarcomas. 11. Identification of novel amplicons at 6p and 17p in osteosarcomas.
Genzes Chroan Canicer 14: 15-21
Gaudray P, Szepetowski P, Escot C, Birnbaum D and Thelliet C (1992) DNA
amplification at Iq13 in human cancer: from complexity to perplexity.
Mltat Res 276: 317-328
Gibbs S, Fijneman R, Wiegant J, Geurts van Kessel A, van de Putte P and
Backendorf C (1993) Molecular characterization and evolution of the SPRR
family of keratinocyte differentiation markers encoding small proline-rich
proteins. Genioinzics 16: 630-637
Heim S, Mandahl N, Kirstoffersson U, Mitelman F, Rooster B, Rydholm A and
Willen H (1987) Marker ring chromosome: a new cytogenetic abnormality
characterizing lipogenetic tumors. Cytogenet Cell Geniet 24: 319-326
Hohl D, de Viragh PA. Amiguet-Barras F, Gibbs S, Backendorf C and Huber M
(1995) The small proline-rich proteins constitute a multigene family of
differentially regulated comified cell envelope processor proteins. J Iniest
Dermnatol 104: 902-909
Huang LS, Bock SC, Feinstein SI and Breslow JL (1985) Human apolipoprotein B
cDNA clone isolation and demonstration that liver apolipoprotein B mRNA is
22 kilo bases in length. Proc Naltl Acad Sci USA 82: 6825-6829
Kallioniemi A, Kallioniemi O-P, Sudar D, Rutovitz D, Gray JW, Waldman F and
Pinkel D (1992) Comparative genomic hybridization for molecular cytogenetic
analysis of solid tumors. Science 258: 818-821
Kallioniemi A. Kallioniemi O-P, Piper J, Tanner M, Stokke T, Chen L, Smith HS,
Pinkel D, Gray JW and Waldman FM (1994) Detection and mapping of
amplified DNA sequences in breast cancer by comparative genomic
hybridization. Proc NaltI Acad Sci USA 91: 2156-2160
British Joumal of Cancer (1998) 78(4), 495-503 C Cancer Research Campaign 19981q21-q22 amplification in human sarcomas 503
Kallioniemi O-P, Kallioniemi A, Piper J, Isola J, Waldman FM, Gray JW and Pinkel
D (1994) Optimizing comparative genomic hybridization for analysis of DNA
sequence copy number changes in solid tumors. Genes Chromosom Cancer 10:
231-243
Khatib ZA, Matsushime H, Valentine M, Shapiro DN, Sherr CJ and Look AT (1993)
Coamplification ofthe CDK4 gene with MDM2 and GLI in human sarcomas.
Cancer Res 53: 5535-5541
Kovacs G (1978) Abnormalities ofchromosome no.1 in human solid malignant
tumours. IntJ Cancer 1: 688-694
Larramendy ML, Tarkkanen M, Blomqvist C, Virolainen M, Wiklund T, Asko-
Seljavaara S, Elomaa I and Knuutila S (1997) Comparative genomic
hybridization of malignant fibrous histiocytoma reveals a novel prognostic
marker. Am J Pathol 151: 1153-1161
Lee SW, Tomasetto C, Swisshelm K, Keyomarsi K and Sager R (1992) Down-
regulation of a member ofthe SI00 gene family in mammary carcinoma cells
and re-expression by azadeoxycytidine treatment. Proc NatlAcad Sci USA 89:
2504-2508
Maelandsmo GM, Berner J-M, Fl0renes VA, Forus A, Hovig E, Fodstad 0 and
Myklebost 0 (1995) Homozygous deletion frequency and expression levels of
the CDKN2 gene in human sarcomas - relationship to amplification and
mRNA levels ofCDK4 and CCND1. BrJ Cancer 72: 393-398
Maelandsmo GM, Fl0renes VA, Mellingsaeter T, Hovig E, Kerberl RS and Fodstad
0 (1997) Differential expression patterns of SI0OA2, SI0OA4 and S10OA6
during progression ofhuman malignant melanoma. Int J Cancer 74: 464-469
Makela TP, Kere J, Winquist R and Alitalo K (1991) Intrachromosomal
rearrangements fusing L-myc and rlf in small-cell lung cancer. Mol Cell Biol
11: 4015-4021
Marenholz I, Volz A, Ziegler A, Davies A, Ragoussis I, Korge BP and Mischke D
(1996) Genetic analysis of the epidermal differentiation complex (EDC) on
human chromosome Iq21: chromosomal orientation, new markers and a 6 Mbp
YAC contig. Genomics 37: 295-302
Muleris M, Almeida A, Gerbault-Seureau M, Malfoy B and Dutrillaux B (1994)
Detection of DNA amplification in 17 primary breast carcinomas with
homogeneously staining regions by modified comparative genomic
hybridization technique. Genes Chromosom Canicer 10: 160-170
Murray JC, Buetow KH, Weber JL, Ludwigsen S, Scherpbier-Heddema T, Manion F,
Quillen J, Sheffield VC, Sunden S, Dukyk GM (Cooperative Human Linkage
Center); Weissenbach J, Gyapay G, Dib C, Morrissette J, Lathrop GM, Vignal
(G6nethon); White R, Matsunami N, Gerken S, Melis R, Alberten H, Plaetke R,
Odelberg S (University ofUtah); Ward D (Yale University); Dausset J, Cohen
D and Cann (Centre d'Etude du Polymorphisme Humain, CEPH) (1994) A
comprehensive human linkage map with centimorgan density. Science 265:
2049-2054
Nau MM, Brooks BJ, Battey J, Sausville E, Gazdar AF, Kirsch IR, McBride OW,
Bertness V, Hollis GF and Minna JD (1985) L-myc, a new myc-related gene
amplified and expressed in human small cell lung cancer. Nature 318: 69-73
Nilbert M, Rydholm A, Willen H, Mitelman F and Mandahl N (1994) MDM2 gene
amplification correlates with ring chromosomes in soft tissue tumors. Genes
Chrom Cancer 9: 261-265
Nilbert M, Rydholm A, Mitelman F, Meltzer PS and Mandahl N (1995)
Characterization ofthe 12q13-15 amplicon in soft tissue sarcomas. Cancer
Genet Cytogenet 83: 32-36
Ormdal C, Mandahl N, Rydholm A, Willen H, Brosjo 0, Heim S and Mitelman F
(1992) Supernumerary ring chromosomes in five bone and soft tissue tumors of
low borderline malignancy. Cancer Genet Cytogenet 60: 170-175
Oshimura M, Sonta S-i and Sandberg AA (1976) Trisomy of the long arm of
chromosome no. I in human leukaemia. J Natl Cancer Inst 56: 183-184
Pedeutour F, Suijkerbuijk RF, Van Gaal J, Van de Klundert W, Coindre J-M, Van
Haelst A, Collin F, Huffermann K and Turc-Carel C (1993) Chromosome 12
origin in rings and giant markers in well-differentiated liposarcoma. Cancer
Genet Cytogenet 66: 133-134
Pedeutour F, Forus A, Coindre J-M, Berner J-M, Nicolo G, Michelis J-F, Terrier P,
Ranchere-Vince D, Collin F, Myklebost 0 and Turc-Carel C (1998) Structure
ofthe supernumerary ring and giant rod chromosomes in adipose tissue
tumours. Gen Chrom Cancer (in press)
Pedeutour F, Suijkerbuijk RF, Forus A, van Gaal J, van de Klundert W, Coindre J-M,
Nicolo G, Collin F, van Haelst U, Huffermann K and Turc-Carel C (1994)
Complex composition and co-amplification of SAS and MDM2 in ring and
giant rod marker chromosomes in well-differentiated liposarcoma. Genes
Chromosom Cancer 10: 85-94
Presland RB, Haydock PV, Fleckman P, Nirunsuksiri W and Dale BA (1992)
Characterization of the human epidermal profilaggrin gene. Genomic
organization and identification of an S-100 like calcium binding domain at the
amino terminus. JBiol Chem 267: 23772-23781
Rogne S, Myklebost 0, H0yheim B, Olaisen B and Gedde Dahl TJ (1989) The genes
for apolipoprotein AII (APOA2) and the Duffy blood group (FY) are linked on
chromosome I in man. Genomics 4: 169-173
Rowley JD (1977) Mapping ofhuman chromosomal regions related to neoplasia:
evidence from chromosome 1 and 17. Proc NatlAcad Sci USA 74: 5729-5733
Schafer BW and Heizmann CW (1996) The SI00 family of EF hand calcium
binding proteins: function and pathology. Trends Biol Sci 21: 134-140
Schafer BW, Wicki R, Engelkamp D, Mattei M-G and Heizmann CW (1995)
Isolation ofa YAC clone covering a cluster of nine SI 00 genes on human
chromosome 1q21: rationale for a new nomenclature ofthe SI00 calcium-
binding protein family. Genomics 25: 638-643
Schajowich F (I1993) Histological Typing ofBone Tumours. Springer-Verlag: Berlin
Swallow DM, Gendler S, Griffiths B, Comey G, Taylor-Papadimitriou J and
Bramwell ME (1987) The human tumour-associated epithelial mucins are
coded by an expressed hyper variable gene locus PUM. Nature 328: 82-84
Szymanska J, Tarkkanen M, Wiklund T, Virolainen M, Blomquist C, Asko-
Seljavaara S, Tukiainen E, Elomaa I and Knuutila S (1996) Gains and losses of
DNA sequences in liposarcomas evaluated by comparative genomic
hybridization. Genes Chrom Cancer 15: 89-94
Szymanska J, Virolainen M, Tarkkanen M, Wiklund T, Asko-Seljavaara S, Tukiainen
E, Elomaa I, Blomqvist C and Knuutila S (1997) Overrepresentation of
lq21-23 and 12q13-21 in lipoma-like liposarcomas but not in benign lipomas:
a comparative genomic hybridization study. Cancer Genet Cytogenet 99: 14-18
Tarkkanen M, Karhu R, Kallioniemi A, Elomaa I, Kivioja AH, Nevalainen J,
Bohling T, Karaharju E, Hyytinen E, Knuutila S and Kallioniemi O-P (1995)
Gains and losses of DNA sequences in osteosarcomas by comparative genomic
hybridization. Cancer Res 55: 1334-1338
Tsarfati I, Hareuveni M, Horev J, Zaretski J, Weiss M, Jeltsch JM, Gamier JM, Lathe
R, Keydar I and Wreschner DH (1990) Isolation and characterization of a
hyper-variable gene coding for breast-cancer associated antigen. Gene 93:
313-318
Tucci A, Goldberger G, Whitehead AS, Kay RM, Woods DE and Colten HR (1983)
Biosynthesis and postsynthetic processing ofhuman C-reactive protein.
JImmunol 131: 2416-2419
Weber-Hall S, Anderson J, McManus A, Abe S, Nojima T, Pinkerton R, Pritchard-
Jones K and Shipley J (1996) Gains, losses and amplification ofgenomic
material in rhabdomyosarcoma analyzed by comparative genomic
hybridization. Cancer Res 56: 3220-3224
Weiss SW (1994) Histological Typing ofSoft Tissue Tumours. Springer-Verlag:
Berlin
Weith A, Brodeur GM, Bruns GA, Matise TC, Mischke D, Nizetic D, Seldin MF,
van Roy N and Vance J (1996) Report ofthe second intemational workshop on
human chromosome 1 mapping 1995. Cytogenet Cell Genet 72: 113-154
Weterman MAJ, Stoopen GM, van Muijen GNP, Kuznick J, Ruiter DJ and Bloemers
HPJ (1992) Expression ofcalcyclin in human melanoma cell lines correlates
with metastatic behaviour in nude mice. CancerRes 52: 1291-1296
Weterman MAJ, Wilbrink M, Dijkhuizen T, van den Berg E and Geurts van Kessel
A (1996) Fine mapping ofthe Iq21 breakpoint ofthe papillary renal cell
carcinoma-associated (X;1) translocation. Hum Genet 98: 16-21
WolfM, Aaltonen LA, Szymanska J, Tarkkanen M, Blomquist C, Bemer J-M,
Myklebost 0 and Knuutila S (1997) Complexity of 12q13-22 amplicon in
liposarcoma: microsatellite repeat analysis. Genes Chrom Cancer 18: 66-70
C Cancer Research Campaign 1998 British Journal ofCancer(1998) 78(4), 495-503